{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:03:20Z","timestamp":1790615000717,"version":"4.1.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.2215\/cjn.08690813","type":"journal-article","created":{"date-parts":[[2014,7,3]],"date-time":"2014-07-03T22:43:32Z","timestamp":1404427412000},"page":"1553-1562","source":"Crossref","is-referenced-by-count":45,"title":["Kidney Function and Plasma Copeptin Levels in Healthy Kidney Donors and Autosomal Dominant Polycystic Kidney Disease Patients"],"prefix":"10.2215","volume":"9","author":[{"given":"Debbie","family":"Zittema","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Else","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy E.","family":"Boertien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke C.","family":"Muller Kobold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casper F.M.","family":"Franssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan J.L.","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerjan","family":"Navis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron T.","family":"Gansevoort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20230601","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1046\/j.1523-1755.2003.00242.x","article-title":"Lillian Jean Kaplan International Prize for advancement in the understanding of polycystic kidney disease. Understanding polycystic kidney disease: A systems biology approach.","volume":"64","author":"Grantham","year":"2003","journal-title":"Kidney Int"},{"key":"R2-10-20230601","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000326902","article-title":"Potential deleterious effects of vasopressin in chronic kidney disease and particularly autosomal dominant polycystic kidney disease.","volume":"34","author":"Meijer","year":"2011","journal-title":"Kidney Blood Press Res"},{"key":"R3-10-20230601","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1681\/ASN.V1171179","article-title":"cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells.","volume":"11","author":"Hanaoka","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"R4-10-20230601","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1093\/ndt\/gfr069","article-title":"Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: Optimal timing and dosing of the drug.","volume":"26","author":"Meijer","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"R5-10-20230601","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","article-title":"Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease.","volume":"10","author":"Torres","year":"2004","journal-title":"Nat Med"},{"key":"R6-10-20230601","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease.","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"R7-10-20230601","doi-asserted-by":"crossref","first-page":"I129","DOI":"10.1161\/01.HYP.5.2_Pt_2.I129","article-title":"Plasma and platelet vasopressin in essential hypertension and congestive heart failure.","volume":"5","author":"Preibisz","year":"1983","journal-title":"Hypertension"},{"key":"R8-10-20230601","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/clinchem\/45.1.98","article-title":"Improved extraction procedure and RIA for determination of arginine8-vasopressin in plasma: Role of premeasurement sample treatment and reference values in children.","volume":"45","author":"Kluge","year":"1999","journal-title":"Clin Chem"},{"key":"R9-10-20230601","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1023\/A:1022564803093","article-title":"Structure-function relationships of the vasopressin prohormone domains.","volume":"18","author":"de Bree","year":"1998","journal-title":"Cell Mol Neurobiol"},{"key":"R10-10-20230601","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1373\/clinchem.2005.060038","article-title":"Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin.","volume":"52","author":"Morgenthaler","year":"2006","journal-title":"Clin Chem"},{"key":"R11-10-20230601","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1210\/jc.2007-0232","article-title":"Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects.","volume":"92","author":"Szinnai","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"R12-10-20230601","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2215\/CJN.04560510","article-title":"Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease.","volume":"6","author":"Meijer","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R13-10-20230601","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.ajkd.2012.08.038","article-title":"Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: Results from the CRISP cohort.","volume":"61","author":"Boertien","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"R14-10-20230601","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1093\/ndt\/gfs070","article-title":"Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease.","volume":"27","author":"Boertien","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"R15-10-20230601","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1042\/CS20080140","article-title":"Gender and renal function influence plasma levels of copeptin in healthy individuals.","volume":"116","author":"Bhandari","year":"2009","journal-title":"Clin Sci (Lond"},{"key":"R16-10-20230601","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ki.2009.397","article-title":"Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort.","volume":"77","author":"Meijer","year":"2010","journal-title":"Kidney Int"},{"key":"R17-10-20230601","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.transproceed.2010.03.138","article-title":"Copeptin in heart transplant recipients depends on kidney function and intraventricular septal thickness.","volume":"42","author":"Przybylowski","year":"2010","journal-title":"Transplant Proc"},{"key":"R18-10-20230601","first-page":"w13270","article-title":"The use of copeptin, the stable peptide of the vasopressin precursor, in the differential diagnosis of sodium imbalance in patients with acute diseases.","volume":"141","author":"Nigro","year":"2011","journal-title":"Swiss Med Wkly"},{"key":"R19-10-20230601","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrneph.2012.139","article-title":"Polycystic kidney disease: An early urea-selective urine-concentrating defect in ADPKD.","volume":"8","author":"Bankir","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"R20-10-20230601","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.2215\/CJN.08761209","article-title":"Renal function equations before and after living kidney donation: A within-individual comparison of performance at different levels of renal function.","volume":"5","author":"Tent","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R21-10-20230601","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(94)92026-5","article-title":"Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1.","volume":"343","author":"Ravine","year":"1994","journal-title":"Lancet"},{"key":"R22-10-20230601","first-page":"97","article-title":"A radioisotope method for simultaneous determination of the glomerular filtration rate and the effective renal plasma flow.","volume":"20","author":"Donker","year":"1977","journal-title":"Neth J Med"},{"key":"R23-10-20230601","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1681\/ASN.V74567","article-title":"Precision of glomerular filtration rate determinations for long-term slope calculations is improved by simultaneous infusion of 125I-iothalamate and 131I-hippuran.","volume":"7","author":"Apperloo","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"R24-10-20230601","first-page":"29","article-title":"Optimising glomerular filtration rate and effective renal plasma flow measurements using a simple pharmacokinetic model.","volume":"43","author":"Zietse","year":"1995","journal-title":"Clin Nephrol"},{"key":"R25-10-20230601","doi-asserted-by":"crossref","first-page":"337","DOI":"10.5414\/CNP72337","article-title":"Glomerular filtration rate measurements by 125I-iothalamate should be corrected for inaccurate urine collections with 131I-hippuran.","volume":"72","author":"Michels","year":"2009","journal-title":"Clin Nephrol"},{"key":"R26-10-20230601","first-page":"303","article-title":"A formula to estimate the approximate surface area if height and weight be known. 1916.","volume":"5","author":"Du Bois","year":"1989","journal-title":"Nutrition"},{"key":"R28-10-20230601","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s00134-012-2691-0","article-title":"Evaluation of 36 formulas for calculating plasma osmolality.","volume":"39","author":"Fazekas","year":"2013","journal-title":"Intensive Care Med"},{"key":"R29-10-20230601","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/ar.a.20017","article-title":"A Homeric view of kidney evolution: A reprint of H.W. Smith\u2019s classic essay with a new introduction. Evolution of the kidney. 1943.","volume":"277","author":"Vize","year":"2004","journal-title":"Anat Rec A Discov Mol Cell Evol Biol"},{"key":"R30-10-20230601","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2215\/CJN.11311111","article-title":"Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment.","volume":"7","author":"Zittema","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"R31-10-20230601","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1681\/ASN.V491654","article-title":"The spectrum of autosomal dominant polycystic kidney disease in children.","volume":"4","author":"Fick","year":"1994","journal-title":"J Am Soc Nephrol"},{"key":"R32-10-20230601","first-page":"629","article-title":"Renal concentrating capacity is linked to blood pressure in children with autosomal dominant polycystic kidney disease.","volume":"53","author":"Seeman","year":"2004","journal-title":"Physiol Res"},{"key":"R33-10-20230601","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/ki.1989.38","article-title":"The clinical utility of renal concentrating capacity in polycystic kidney disease.","volume":"35","author":"Gabow","year":"1989","journal-title":"Kidney Int"},{"key":"R34-10-20230601","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/ki.1983.51","article-title":"Rate of functional deterioration in polycystic kidney disease.","volume":"23","author":"Franz","year":"1983","journal-title":"Kidney Int"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201409000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:43:23Z","timestamp":1786369403000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201409000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.08690813","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]}}}